Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 26 , ISSUE S2 ( October, 2022 ) > List of Articles


Guidelines for the Use of Procalcitonin for Rational Use of Antibiotics

Gopi Chand Khilnani, Pawan Tiwari, Dhruva Chaudhry, Subhal Dixit, Atul Prabhakar Kulkarni, Subhash Kumar Todi, Vijay Hadda, Neetu Jain, Manjunath B Govindagoudar, Simant Kumar Jha, Niraj Tyagi, Madhusudan R Jaju, Anita Sharma

Keywords : Antibiotics, Guidelines, Procalcitonin, Sepsis, Stewardship

Citation Information :

DOI: 10.5005/jp-journals-10071-24326

License: CC BY-NC 4.0

Published Online: 31-10-2022

Copyright Statement:  Copyright © 2022; The Author(s).


PDF Share
  1. Antimicrobial resistance. Available at: 2022. Accessed on: 1st May 2022.
  2. Carlet J, Pulcini C, Piddock LJV. Antibiotic resistance: A geopolitical issue. Clin Microbiol Infect 2014;20(10):949–953. DOI: 10.1111/1469-0691.12767.
  3. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, et al. Antibiotic resistance: The need for global solutions. Lancet Infect Dis 2013;13(12):1057–1098. DOI: 10.1016/S1473-3099(13)70318-9.
  4. Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016;62(10):e51–e77. DOI: 10.1093/cid/ciw118.
  5. Snider RH, Nylen ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med 1997;45(9):552–560. PMID: 9444882.
  6. Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: A harmful biomarker and a therapeutic target. Br J Pharmacol 2010;159(2):253–264. DOI: 10.1111/j.1476-5381.2009.00433.x.
  7. Schuetz P, Bolliger R, Merker M, Christ–Crain M, Stolz D, Tamm M, et al. Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials. Expert Rev. Anti Infect Therapy 2018;16(7):555–564. DOI: 10.1080/14787210.2018.1496331.
  8. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994;79(6):1605–1608. DOI: 10.1210/jcem.79.6.7989463.
  9. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341(8844):515–518. DOI: 10.1016/0140-6736(93)90277-n.
  10. Pontrelli G, De Crescenzo F, Buzzetti R, Jenkner A, Balduzzi S, Calò Carducci F, et al. Accuracy of serum procalcitonin for the diagnosis of sepsis in neonates and children with systemic inflammatory syndrome: A meta-analysis. BMC Infect Dis 2017;17(1):302. DOI: 10.1186/s12879-017-2396-7.
  11. Tan M, Lu Y, Jiang H, Zhang L. The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis: A systematic review and meta-analysis. J Cell Biochem 2019;120(4):5852–5859. DOI: 10.1002/jcb.27870.
  12. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Crit Care Med 2021;49(11):e1063–e1143. DOI: 10.1097/CCM.0000000000005337.
  13. Gutiérrez–Pizarraya A, León–García MDC, De Juan–Idígoras R, Garnacho–Montero J. Clinical impact of procalcitonin-based algorithms for duration of antibiotic treatment in critically ill adult patients with sepsis: A meta-analysis of randomized clinical trials. Expert Rev Anti Infect Therapy 2022;20(1):103–112. DOI: 10.1080/14787210.2021.
  14. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 2006;34(2):344–353. DOI: 10.1097/01.ccm.0000194725.48928.3a.
  15. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302(21):2323–2329. DOI: 10.1001/jama.2009.1754.
  16. Anand D, Das S, Bhargava S, Srivastava LM, Garg A, Tyagi N, et al. Procalcitonin as a rapid diagnostic biomarker to differentiate between culture-negative bacterial sepsis and systemic inflammatory response syndrome: A prospective, observational, cohort study. J Crit Care 2015;30(1):218.e7–218.e12. DOI: 10.1016/j.jcrc.2014.08.017.
  17. Zhang T, Wang Y, Yang Q, Dong Y. Procalcitonin-guided antibiotic therapy in critically ill adults: A meta-analysis. BMC Infect Dis 2017;17(1):514. DOI: 10.1186/s12879-017-2622-3.
  18. Andriolo BN, Andriolo RB, Salomão R, Atallah ÁN. Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev 2017;1(1):CD010959. DOI: 10.1002/14651858.CD010959.pub2.
  19. Pepper DJ, Sun J, Rhee C, Welsh J, Powers JH, Danner RL, et al. Procalcitonin-guided antibiotic discontinuation and mortality in critically ill adults. Chest 2019;155(6):1109–1118. DOI: 10.1016/j.chest.2018.12.029.
  20. Wirz Y, Meier MA, Bouadma L, Luyt CE, Wolff M, Chastre J, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: A patient-level meta-analysis of randomized trials. Crit Care 2018;22(1):191.
  21. Elnajdy D, El-Dahiyat F. Antibiotics duration guided by biomarkers in hospitalized adult patients: A systematic review and meta-analysis. Infect Dis (Lond) 2022;54(6):387–402. DOI: 10.1080/23744235.2022.2037701.
  22. Vishalashi SG, Gupta P, Verma PK. Serum procalcitonin as a biomarker to determine the duration of antibiotic therapy in adult patients with sepsis and septic shock in intensive care units: A prospective study. Indian J Crit Care Med 2021;25(5):507–511. DOI: 10.5005/jp-journals-10071-23802.
  23. Heilmann E, Gregoriano C, Wirz Y, Luyt CE, Wolff M, Chastre J, et al. Association of kidney function with effectiveness of procalcitonin-guided antibiotic treatment: A patient-level meta-analysis from randomized controlled trials. Clin Chem Lab Med (CCLM) 2021;59(2):441–453. DOI: 10.1515/cclm-2020-0931.
  24. Robati Anaraki M, Nouri–Vaskeh M, Abdoli Oskouie S. Effectiveness of procalcitonin-guided antibiotic therapy to shorten treatment duration in critically-ill patients with bloodstream infections: A systematic review and meta-analysis. Infez Med 2020;28(1):37–46. PMID: 32172259.
  25. Voermans AM, Mewes JC, Broyles MR, Steuten LMG. Cost-effectiveness analysis of a procalcitonin-guided decision algorithm for antibiotic stewardship using real-world U.S. hospital data. OMICS 2019;23(10):508–515. DOI: 10.1089/omi.2019.0113.
  26. Chow J, Markossian TW, Albarillo FS, Donahey EE, Bobay KL. Impact of a procalcitonin-based protocol on antibiotic exposure and costs in critically ill patients. Crit Care Explor 2021;3(11):e0571. DOI: 10.1097/CCE.0000000000000571.
  27. Jeon K, Suh JK, Jang EJ, Cho S, Ryu HG, Na S, et al. Procalcitonin-guided treatment on duration of antibiotic therapy and cost in septic patients (PRODA): A multi-center randomized controlled trial. J Korean Med Sci 2019;34(14):e110. DOI: 10.3346/jkms.2019.34.e110.
  28. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: A randomized trial. Am J Respir Crit Care Med 2008;177(5):498–505. DOI: 10.1164/rccm.200708-1238OC.
  29. Xu XL, Yan FD, Yu JQ, Chen QH, Lin H, Zheng RQ. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment of sepsis patients. Zhonghua Yi Xue Za Zhi 2017;97(5): 343–346. DOI: 10.3760/cma.j.issn.0376-2491.2017.05.005.
  30. Shehabi Y, Sterba M, Garrett PM, Rachakonda KS, Stephens D, Harrigan P, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med 2014;190(10):1102–10. DOI: 10.1164/rccm.201408-1483OC.
  31. Hochreiter M, Köhler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009;13(3):R83. DOI: 10.1186/cc7903.
  32. Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: Results of a prospective randomized study. Langenbecks Arch Surg 2009;394(2):221–226. DOI: 10.1007/s00423-008-0432-1.
  33. Liu Bh, Li Hf, Lei Y, Zhao Sx, Sun Ml. Clinical significance of dynamic monitoring of procalcitonin in guiding the use of antibiotics in patients with sepsis in ICU. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2013;25(11):690–693. DOI: 10.3760/cma.j.issn.2095-4352.2013. 11.013.
  34. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomised, controlled, open-label trial. Lancet Infect Dis 2016;16(7):819–827. DOI: 10.1016/S1473-3099(16)00053-0.
  35. Annane D, Maxime V, Faller JP, Mezher C, Clec'h C, Martel P, et al. Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: A randomised controlled trial. BMJ Open 2013;3(2):e002186. DOI: 10.1136/bmjopen-2012-002186.
  36. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagn Microbiol Infect Dis 2013;76(3):266–271. DOI: 10.1016/j.diagmicrobio.2013. 03.027.
  37. Oliveira CF, Botoni FA, Oliveira CRA, Silva CB, Pereira HA, Serufo JC, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: A randomized trial. Crit Care Med 2013;41(10): 2336–2343. DOI: 10.1097/CCM.0b013e31828e969f.
  38. Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK, Jaschinski U, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: A randomized clinical trial. JAMA Intern Med 2016;176(9):1266–1276. DOI: 10.1001/jamainternmed.2016.2514.
  39. Sager R, Wirz Y, Amin D, Amin A, Hausfater P, Huber A, et al. Are admission procalcitonin levels universal mortality predictors across different medical emergency patient populations? Results from the multi-national, prospective, observational TRIAGE study. Clin Chem Lab Med 2017;55(12):1873–1880. DOI: 10.1515/cclm-2017-0144.
  40. Schuetz P, Birkhahn R, Sherwin R, Jones AE, Singer A, Kline JA, et al. Serial procalcitonin predicts mortality in severe sepsis patients: Results from the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study. Crit Care Med 2017;45(5):781–789. DOI: 10.1097/CCM.0000000000002321.
  41. Jekarl DW, Lee S, Kim M, Kim Y, Woo SH, Lee WJ. Procalcitonin as a prognostic marker for sepsis based on SEPSIS-3. J Clin Lab Anal. 2019;33(9):e22996. DOI: 10.1002/jcla.22996
  42. Stockmann C, Ampofo K, Killpack J, Williams DJ, Edwards KM, Grijalva CG, et al. Procalcitonin accurately identifies hospitalized children with low risk of bacterial community-acquired pneumonia. J Pediatric Infect Dis Soc 2018;7(1):46–53. DOI: 10.1093/jpids/piw091.
  43. Self WH, Balk RA, Grijalva CG, Williams DJ, Zhu Y, Anderson EJ, et al. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis 2017;65(2):183–190. DOI: 10.1093/cid/cix317.
  44. Rao K, Walk ST, Micic D, Chenoweth E, Deng L, Galecki AT, et al. Procalcitonin levels associate with severity of Clostridium difficile infection. PLoS One 2013;8(3):e58265. DOI: 10.1371/journal.pone. 0058265.
  45. Shapiro DS, Friedmann R, Husseini A, Ivgi H, Yinnon AM, Assous MV. Can procalcitonin contribute to the diagnosis of Clostridium difficile colitis? Isr Med Assoc J 2017;19(5):313–316. PMID: 28513121.
  46. Raineri SM, Cortegiani A, Vitale F, Iozzo P, Giarratano A. Procalcitonin for the diagnosis of invasive candidiasis: What is the evidence? J Intensive Car. 2017;5:58. DOI: 10.1186/s40560-017-0252-x.
  47. Charles PE, Dalle F, Aho S, Quenot JP, Doise JM, Aube H, et al. Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients. Intensive Care Med 2006;32(10):1577–1578. DOI: 10.1007/s00134-006-0306-3.
  48. Uzzan B, Izri A, Durand R, Deniau M, Bouchaud O, Perret GY. Serum procalcitonin in uncomplicated falciparum malaria: A preliminary study. Travel Med Infect Dis 2006;4(2):77–80. DOI: 10.1016/j.tmaid. 2005.04.003.
  49. Chiwakata CB, Manegold C, Bönicke L, Waase I, Jülch C, Dietrich M. Procalcitonin as a parameter of disease severity and risk of mortality in patients with Plasmodium falciparum malaria. J Infect Dis 2001;183(7):1161–1164. DOI: 10.1086/319283.
  50. Ugajin M, Miwa S, Shirai M, Ohba H, Eifuku T, Nakamura H, et al. Usefulness of serum procalcitonin levels in pulmonary tuberculosis. Eur Respir J 2011;37(2):371–375. DOI: 10.1183/09031936.00011910.
  51. Rasmussen TA, Søgaard OS, Camara C, Andersen PL, Wejse C. Serum procalcitonin in pulmonary tuberculosis. Int J Tubercul Lung Dis 2011;15(2):251–256. PMID: 21219690.
  52. Christensen AMG, Thomsen MK, Ovesen T, Klug TE. Are procalcitonin or other infection markers useful in the detection of group A streptococcal acute tonsillitis? Scand J Infect Dis 2014;46(5):376–383. DOI: 10.3109/00365548.2014.885656.
  53. Pallin DJ, Bry L, Dwyer RC, Lipworth AD, Leung DY, Camargo CA Jr, et al. Toward an objective diagnostic test for bacterial cellulitis. PLoS One 2016;11(9):e0162947. DOI: 10.1371/journal.pone.0162947.
  54. Roques M, Chretien ML, Favennec C, Lafon I, Ferrant E, Legouge C, et al. Evolution of procalcitonin, C-reactive protein and fibrinogen levels in neutropenic leukaemia patients with invasive pulmonary aspergillosis or mucormycosis. Mycoses 2016;59(6):383–390. DOI: 10.1111/myc.12487.
  55. Sakata KK, Grys TE, Chang YHH, Vikram HR, Blair JE. Serum procalcitonin levels in patients with primary pulmonary coccidioidomycosis. Ann Am Thorac Soc 2014;11(8):1239–1243. DOI: 10.1513/AnnalsATS.201404-180BC.
  56. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. New Eng J Med 2018;379(3):236–249. DOI: 10.1056/NEJMoa1802670.
  57. Schuetz P, Wirz Y, Sager R, Christ–Crain M, Stolz D, Tamm M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2017;10(1)):CD007498. DOI: 10.1002/14651858.CD007498.pub3.
  58. Kamat IS, Ramachandran V, Eswaran H, Abers MS, Musher DM. Low procalcitonin, community acquired pneumonia, and antibiotic therapy. Lancet Infect Dis 2018;18(5):496–497. DOI: 10.1016/S1473-3099(18)30215-9.
  59. Huang DT, Yealy DM, Angus DC. Longer-term outcomes of the ProACT trial. N Engl J Med 2020;382(5):485–486. DOI: 10.1056/NEJMc1910508.
  60. DeSear KE, Thompson–Leduc P, Kirson N, Chritton JJ, Ie S, Van Schooneveld TC, et al. ProCommunity: Procalcitonin use in real-world US community hospital settings. Curr Med Res Opin 2020;36(9): 1529–1532. DOI: 10.1080/03007995.2020.1793748.
  61. Vaughn VM, Gandhi TN, Petty LA, Patel PK, Prescott HC, Malani AN, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): A multi-hospital cohort study. Clin Infect Dis 2021;72(10):e533–e541. DOI: 10.1093/cid/ciaa1239.
  62. Jackson I, Jaradeh H, Aurit S, Aldamen A, Narechania S, Destache C, et al. Role of procalcitonin as a predictor of clinical outcomes in hospitalized patients with COVID-19. Int J Infect Dis 2022;119:47–52. DOI: 10.1016/j.ijid.2022.03.044.
  63. Vazzana N, Dipaola F, Ognibene S. Procalcitonin and secondary bacterial infections in COVID-19: Association with disease severity and outcomes. Acta Clinica Belgica 2022;77(2):268–272. DOI: 10.1080/17843286.2020.1824749.
  64. Tong–Minh K, van der Does Y, Engelen S, de Jong E, Ramakers C, Gommers D, et al. High procalcitonin levels associated with increased intensive care unit admission and mortality in patients with a COVID-19 infection in the emergency department. BMC Infect Dis 2022;22(1):165. DOI: 10.1186/s12879-022-07144-5.
  65. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta 2020;505:190–191. DOI: 10.1016/j.cca.2020.03.004.
  66. Llewelyn MJ, Grozeva D, Howard P, Euden J, Gerver SM, Hope R, et al. Impact of introducing procalcitonin testing on antibiotic usage in acute NHS hospitals during the first wave of COVID-19 in the UK: A controlled interrupted time series analysis of organization-level data. J Antimicrob Chemother 2022;77(4):1189–1196. DOI: 10.1093/jac/dkac017.
  67. Gupta D, Agarwal R, Aggarwal AN, Singh N, Mishra N, Khilnani GC, et al. Guidelines for diagnosis and management of community-and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations. Lung India 2012;29(6):27. DOI: 10.4103/0970-2113.99248.
  68. Khilnani, G, Zirpe, K, Hadda, V, Mehta, Y, Madan, K, Kulkarni, A, et al. Guidelines for antibiotic prescription in intensive care unit. Indian J Crit Care Med 2019;23(Suppl. 1):S1–S63. DOI: 10.5005/jp-journals-10071-23101.
  69. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019;200(7):e45–e67. DOI: 10.1164/rccm.201908-1581ST.
  70. Kamat IS, Ramachandran V, Eswaran H, Guffey D, Musher DM. Procalcitonin to distinguish viral from bacterial pneumonia: A systematic review and meta-analysis. Clin Infect Dis 2020;70(3): 538–542. DOI: 10.1093/cid/ciz545.
  71. Fabre V, Karaba S, Amoah J, Robinson M, Jones G, Dzintars K, et al. The role of procalcitonin results in antibiotic decision-making in coronavirus disease 2019 (COVID-19). Infect Control Hosp Epidemiol 2022;43(5):570–575. DOI: 10.1017/ice.2021.175.
  72. Ito A, Ishida T, Tokumasu H, Washio Y, Yamazaki A, Ito Y, et al. Impact of procalcitonin-guided therapy for hospitalized community-acquired pneumonia on reducing antibiotic consumption and costs in Japan. J Infect Chemother 2017;23(3):142–147.
  73. Montassier E, Javaudin F, Moustafa F, Nandjou D, Maignan M, Hardouin JB, et al. Guideline-based clinical assessment versus procalcitonin-guided antibiotic use in pneumonia: A pragmatic randomized trial. Ann Emerg Med 2019;74(4):580–591. DOI: 10.1016/j.annemergmed.2019.02.025.
  74. Song YY, Zhang B, Gu JW, Zhang YJ, Wang Y. The predictive value of procalcitonin in ventilator-associated pneumonia after cardiac valve replacement. Scand J Clin Lab Invest 2020;80(5):423–426. DOI: 10.1080/00365513.2020.1762242.
  75. Sotillo–Díaz JC, Bermejo–López E, García–Olivares P, Peral–Gutiérrez JA, Sancho–González M, Guerrero–Sanz JE. Role of plasma procalcitonin in the diagnosis of ventilator-associated pneumonia: Systematic review and metaanalysis. Med Intensiva 2014;38(6): 337–346. DOI: 10.1016/j.medin.2013.07.001.
  76. Póvoa P, Martin–Loeches I, Ramirez P, Bos LD, Esperatti M, Silvestre J, et al. Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study. Ann Intensive Care 2016;6(1):32. DOI: 10.1186/s13613-016-0134-8.
  77. Jung B, Embriaco N, Roux F, Forel JM, Demory D, Allardet–Servent J, et al. Microbiogical data, but not procalcitonin improve the accuracy of the clinical pulmonary infection score. Intensive Care Med 2010;36(5):790–798. DOI: 10.1007/s00134-010-1833-5.
  78. Re MFC, Rocchetti NS, Settecase CJ, Bagilet DH. Diagnostic value of procalcitonin in ventilator-associated pneumonia. Med Clin (Barc) 2019;152(6):216–221. DOI: 10.1016/j.medcli.2018.06.019.
  79. Rahimibashar F, Miller AC, Yaghoobi MH, Vahedian–Azimi A. A comparison of diagnostic algorithms and clinical parameters to diagnose ventilator-associated pneumonia: A prospective observational study. BMC Pulm Med 2021;21(1):161. DOI: 10.1186/s12890-021-01527-1.
  80. Zhou J, Song J, Gong S, Hu W, Wang M, Xiao A, et al. Lung ultrasound combined with procalcitonin for a diagnosis of ventilator-associated pneumonia. Respir Care 2019;64(5):519–527. DOI: 10.4187/respcare.06377.
  81. Coelho L, Rabello L, Salluh J, Martin–Loeches I, Rodriguez A, Nseir S, et al. C-reactive protein and procalcitonin profile in ventilator-associated lower respiratory infections. J Crit Care 2018;48:385–389. DOI: 10.1016/j.jcrc.2018.09.036.
  82. Li B, Zhao X, Li S. Serum procalcitonin level and mortality risk in critically ill patients with ventilator-associated pneumonia. CPB 2015;37(5):1967–1972. DOI: 10.1159/000438557.
  83. Bloos F, Marshall JC, Dellinger RP, Vincent JL, Gutierrez G, Rivers E, et al. Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: A multicenter observational study. Crit Care 2011;15(2):R88. DOI: 10.1186/cc10087.
  84. Tanrıverdi H, Tor MM, Kart L, Altın R, Atalay F, SumbSümbüloğlu V. Prognostic value of serum procalcitonin and C-reactive protein levels in critically ill patients who developed ventilator-associated pneumonia. Ann Thorac Med 2015;10(2):137–142. DOI: 10.4103/1817-1737.151442.
  85. Hillas G, Vassilakopoulos T, Plantza P, Rasidakis A, Bakakos P. C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia. Eur Respir J 2010;35(4):805–811. DOI: 10.1183/09031936.00051309.
  86. Torres A, Niederman MS, Chastre J, Ewig S, Fernandez–Vandellos P, Hanberger H, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J 2017;50(3): 1700582. DOI: 10.1183/13993003.00582-2017.
  87. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63(5):e61–e111. DOI: 10.1093/cid/ciw353.
  88. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009; 34(6):1364–1375. DOI: 10.1183/09031936.00053209.
  89. Mazlan MZ, Ismail MAH, Ali S, Salmuna ZN, Shukeri WFWM, Omar M. Efficacy and safety of the point-of-care procalcitonin test for determining the antibiotic treatment duration in patients with ventilator-associated pneumonia in the intensive care unit: A randomised controlled trial. Anaesthesiol Intensive Therapy 2021;53(3):207–214. DOI: 10.5114/ait.2021.104300.
  90. Wongsurakiat P, Tulatamakit S. Clinical pulmonary infection score and a spot serum procalcitonin level to guide discontinuation of antibiotics in ventilator-associated pneumonia: a study in a single institution with high prevalence of non-fermentative gram-negative bacilli infection. Ther Adv Respir Dis 2018;12:1753466618760134. DOI: 10.1177/1753466618760134.
  91. Beye F, Vigneron C, Dargent A, Prin S, Andreu P, Large A, et al. Adhering to the procalcitonin algorithm allows antibiotic therapy to be shortened in patients with ventilator-associated pneumonia. J Crit Care 2019;53:125–131. DOI: 10.1016/j.jcrc.2019.05.022.
  92. Pontet J, Bazzano F, Miraballes R, Bentancourt S, Cancela M. Procalcitonin (PCT) guided antibiotic treatment in ventilator associated pneumonia (VAP). Multi–centre, clinical prospective, randomized–controlled study. Index Infectológico 2008;175:63.
  93. Huespe I, Prado E, Staneloni I, Contrera N, Denaday L, San Roman E, et al. Kinetics of procalcitonin in infections caused by multidrug-resistant bacteria. Medicina (B Aires). 2020;80(6):599–605. PMID: 33254103.
  94. van Nieuwkoop C, Bonten TN, van't Wout JW, Kuijper EJ, Groeneveld GH, Becker MJ, et al. Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Crit Care 2010;14(6):R206. DOI: 10.1186/cc9328.
  95. Julián–Jiménez A, Gutiérrez–Martín P, Lizcano–Lizcano A, López–Guerrero MA, Barroso–Manso Á, Heredero-Gálvez E. Usefulness of procalcitonin and C-reactive protein for predicting bacteremia in urinary tract infections in the emergency department. Actas Urol Esp 2015;502–510. DOI: 10.1016/j.acuro.2015.03.003.
  96. Lee H, Lee YS, Jeong R, Kim YJ, Ahn S. Predictive factors of bacteremia in patients with febrile urinary tract infection: An experience at a tertiary care center. Infection 2014;42(4):669–674. DOI: 10.1007/s15010-014-0615-3.
  97. Levine AR, Tran M, Shepherd J, Naut E. Utility of initial procalcitonin values to predict urinary tract infection. Am J Emerg Med 2018;36(11):1993–1997. doi: 10.1016/j.ajem.2018.03.001.
  98. Luo X, Yang X, Li J, Zou G, Lin Y, Qing G, et al. The procalcitonin/albumin ratio as an early diagnostic predictor in discriminating urosepsis from patients with febrile urinary tract infection. Medicine (Baltimore) 2018;97(28):e11078. DOI: 10.1097/MD.0000000000011078.
  99. Drozdov D, Schwarz S, Kutz A, Grolimund E, Rast AC, Steiner D, et al. Procalcitonin and pyuria-based algorithm reduces antibiotic use in urinary tract infections: A randomized controlled trial. BMC Med 2015;13:104. DOI: 10.1186/s12916-015-0347-y.
  100. Stalenhoef JE, van Nieuwkoop C, Wilson DC, van der Starre WE, Delfos NM, Leyten EMS, et al. Biomarker guided triage can reduce hospitalization rate in community acquired febrile urinary tract infection. J Infect 2018;77(1):18–24. DOI: 10.1016/j.jinf.2018.05.007.
  101. Villarreal E, Vacacela K, Gordon M, Calabuig C, Alonso R, Ruiz J, et al. Usefulness of procalcitonin for diagnosing infection in critically ill patients with liver cirrhosis. Med Intensiva 2016;40(2):84–89. DOI: 10.1016/j.medin.2015.02.006.
  102. Yuan LY, Ke ZQ, Wang M, Li Y. Procalcitonin and C-reactive protein in the diagnosis and prediction of spontaneous bacterial peritonitis associated with chronic severe hepatitis B. Ann Lab Med 2013;33(6):449–454. DOI: 10.3343/alm.2013.33.6.449.
  103. Yang Y, Li L, Qu C, Zeng B, Liang S, Luo Z, et al. Diagnostic accuracy of serum procalcitonin for spontaneous bacterial peritonitis due to end-stage liver disease: A meta-analysis. Medicine (Baltimore) 2015;94(49):e2077. DOI: 10.1097/MD.0000000000002077.
  104. Wang H, Li Y, Zhang F, Yang N, Xie N, Mao Y, et al. Combination of PCT, sNFI and dCHC for the diagnosis of ascites infection in cirrhotic patients. BMC Infect Dis 2018;18(1):389. DOI: 10.1186/s12879-018- 3308-1.
  105. Woo SM, Noh MH, Kim BG, Hsing CT, Han JS, Ryu SH, et al. Comparison of serum procalcitonin with Ranson, APACHE-II, Glasgow and Balthazar CT severity index scores in predicting severity of acute pancreatitis. Korean J Gastroenterol 2011;58(1):31–37. DOI: 10.4166/kjg.2011.58.1.31.
  106. Qu R, Ji Y, Ling Y, Ye CY, Yang SM, Liu YY, et al. Procalcitonin is a good tool to guide duration of antibiotic therapy in patients with severe acute pancreatitis. A randomized prospective single-center controlled trial. Saudi Med J 2012;33(4):382–387.
  107. Abdel–Razik A, Mousa N, Elhammady D, Elhelaly R, Elzehery R, Elbaz S, et al. Ascitic fluid calprotectin and serum procalcitonin as accurate diagnostic markers for spontaneous bacterial peritonitis. Gut Liver 2016;10(4):624–631. DOI: 10.5009/gnl15120.
  108. Yang Sk, Xiao L, Zhang H, Xu X xuan, Song P ai, Liu F you, et al. Significance of serum procalcitonin as biomarker for detection of bacterial peritonitis: A systematic review and meta-analysis. BMC Infect Dis 2014;14(1):452. DOI: 10.1186/1471-2334-14-452.
  109. Pupelis G, Drozdova N, Mukans M, Malbrain MLNG. Serum procalcitonin is a sensitive marker for septic shock and mortality in secondary peritonitis. Anaesthesiol Intensive Ther 2014;46(4): 262–273. DOI: 10.5603/AIT.2014.0043.
  110. Akcay I, Okoh AK, Yalav O, Eray IC, Rencuzogullari A, Dalci K, et al. The prognostic value of pro-calcitonin, CRP and thyroid hormones in secondary peritonitis: A single-center prospective study. Ulus Travma Acil Cerrahi Derg 2014;20(5):343–352. DOI: 10.5505/tjtes.2014.98354.
  111. Huang TS, Huang SS, Shyu YC, Lee CH, Jwo SC, Chen PJ, et al. A procalcitonin-based algorithm to guide antibiotic therapy in secondary peritonitis following emergency surgery: A prospective study with propensity score matching analysis. PLoS One 2014;9(3):e90539. DOI: 10.1371/journal.pone.0090539.
  112. Maseda E, Suarez-de-la-Rica A, Anillo V, Tamayo E, García–Bernedo CA, Ramasco F, et al. Procalcitonin-guided therapy may reduce length of antibiotic treatment in intensive care unit patients with secondary peritonitis: A multicenter retrospective study. J Crit Care 2015;30(3):537–542. DOI: 10.1016/j.jcrc.2014.12.014.
  113. El Haddad H, Chaftari AM, Hachem R, Chaftari P, Raad II. Biomarkers of sepsis and bloodstream infections: The role of procalcitonin and proadrenomedullin with emphasis in patients with cancer. Clin Infect Dis 2018;67(6):971–977. DOI: 10.1093/cid/ciy331.
  114. Bele N, Darmon M, Coquet I, Feugeas JP, Legriel S, Adaoui N, et al. Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients. BMC Infect Dis 2011;11:224. DOI: 10.1186/1471-2334-11-224.
  115. Stolz D, Stulz A, Müller B, Gratwohl A, Tamm M. BAL neutrophils, serum procalcitonin, and C-reactive protein to predict bacterial infection in the immunocompromised host. Chest 2007;132(2):504–514. DOI: 10.1378/chest.07-0175.
  116. Savaş Bozbaş Ş, Er Dedekargınoğlu B, Ulubay G, Haberal M. Role of serum procalcitonin levels in solid-organ transplant patients. Exp Clin Transplant 2016;14(Suppl. 3):116–120. PMID: 27805529.
  117. Mauro MV, Cavalcanti P, Perugini D, Noto A, Sperlì D, Giraldi C. Diagnostic utility of LightCycler SeptiFast and procalcitonin assays in the diagnosis of bloodstream infection in immunocompromised patients. Diagn Microbiol Infect Dis 2012;73(4):308–311. DOI: 10.1016/j.diagmicrobio.2012.04.006.
  118. Gunasekaran V, Radhakrishnan N, Dinand V, Sachdeva A. Serum procalcitonin for predicting significant infections and mortality in pediatric oncology. Indian Pediatr 2016;53(12):1075–1078. PMID: 27889712.
  119. Vyles D, Gnagi F, Bulloch B, Muenzer J, Hu C. Procalcitonin as a marker of bacteremia in patients with fever and acute lymphoblastic leukemia. Pediatr Emerg Care 2016;32(9):590–593. DOI: 10.1097/PEC.0000000000000660.
  120. Lin KH, Wang FL, Wu MS, Jiang BY, Kao WL, Chao HY, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: a systematic review and meta-analysis. Diagn Microbiol Infect Dis 2014;80(1):72–78. DOI: 10.1016/j.diagmicrobio.2014.03.029.
  121. Schüttrumpf S, Binder L, Hagemann T, Berkovic D, Trümper L, Binder C. Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato–oncological patients? Ann Hematol 2003;82(2):98–103. DOI: 10.1007/s00277-002-0584-y.
  122. Marková M, Brodská H, Malíčková K, Válková V, Cetkovský P, Kolář M, et al. Substantially elevated C-reactive protein (CRP), together with low levels of procalcitonin (PCT), contributes to diagnosis of fungal infection in immunocompromised patients. Support Care Cancer 2013;21(10):2733–2742. DOI: 10.1007/s00520-013-1844-1.
  123. Stoma I, Karpov I, Uss A, Krivenko S, Iskrov I, Milanovich N, et al. Combination of sepsis biomarkers may indicate an invasive fungal infection in haematological patients. Biomarkers 2019;24(4):401–406. DOI: 10.1080/1354750X.2019.1600023.
  124. Sammons C, Doligalski CT. Utility of procalcitonin as a biomarker for rejection and differentiation of infectious complications in lung transplant recipients. Ann Pharmacother 2014;48(1):116–122. DOI: 10.1177/1060028013508085.
  125. Arora R, Sahni N. Can serum procalcitonin aid in the diagnosis of blood stream infection in patients on immunosuppressive medications? Clin Chim Acta 2018;483:204–208. DOI: 10.1016/j.cca.2018.05.002.
  126. Mikuła T, Cianciara J, Wiercińska–Drapało A. Is there any influence of immune deficit on procalcitonin results? Hum Immunol 2011;72(12):1194–1197. DOI: 10.1016/j.humimm.2011.08.018.
  127. Shomali W, Hachem R, Chaftari AM, Jiang Y, Bahu R, Jabbour J, et al. Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients? Cancer 2012;118(23): 5823–5829. DOI: 10.1002/cncr.27602.
  128. al-Nawas B, Shah PM. Procalcitonin in patients with and without immunosuppression and sepsis. Infection 1996;24(6):434–436. DOI: 10.1007/BF01713044.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.